[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100486356":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":30,"responsibleParty":48,"collaborators":50,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":20,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":20,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":77,"overallStatus":33,"whyStopped":20,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Johns Hopkins University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Mobile health (mHealth) text messaging intervention","EXPERIMENTAL","During baseline (4 weeks), adherence will be monitored daily via electronic pill boxes and no text messages will be sent. After baseline, participants will begin the 12-week micro-randomized trial of the intervention (a within-person study design). During this 12-week micro-randomized trial, daily adherence will be electronically monitored with the electronic pill boxes and participants will be randomized to receive (1) adherence support text messages or (2) no text message after each missed dose, and (1) praise text message or (2) no text message after each on time dose. For 12 months post-intervention, participants will keep using the electronic pill boxes (no text messages will be sent).",[13],"Behavioral: mHealth Messaging Intervention Group",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BEHAVIORAL","mHealth Messaging Intervention Group","Participants will receive an electronic pill box; the research team will instruct participants on how to use this device. Participants will be asked to use the electronic pill box for their prescribed medicines for the duration of the study (up to 16 months). During the 12-week micro-randomized trial, participants will be randomized within person to receive (1) adherence support text messages or (2) no text message after each missed dose, and (1) praise text message or (2) no text message after each on time dose. Dose timing will be determined based on participant report of when they typically take their tacrolimus or sirolimus medicine.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Cyd Eaton, PhD","PRINCIPAL_INVESTIGATOR",[26],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","667-306-6201","ceaton4@jhmi.edu",[31],{"facility":32,"status":33,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Johns Hopkins","RECRUITING","Baltimore","Maryland","21287","United States","US",{"type":40,"coordinates":41},"Point",[42,43],-76.61219,39.29038,{"lat":43,"lon":42},[46,47],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":49,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR",[51],{"name":52,"class":53},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100486356","leveraging-technology-to-improve-medication-adherence-in-youth-with-kidney-or-liver-transplant-100486356",false,"NCT05613010","Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant","Leveraging Technology to Improve Medication Adherence in Adolescent and Young Adult Kidney or Liver Transplant Recipients: A Micro-Randomized Trial","Inclusion Criteria:\n\n* Adolescents and young adults (13-25 years old) who underwent kidney or liver transplantation at least 6 months prior to enrollment\n* Currently prescribed tacrolimus or sirolimus.\n\nExclusion Criteria:\n\n* Currently receiving dialysis\n* Hospitalized for duration of study\n* Significant developmental or cognitive delay\n* No access to a mobile device that supports text messaging\n* Decline to use electronic pill box to monitor daily medication adherence\n* Non-English speaking\n* If a participant meets inclusion criteria, enrolls in the study, and experiences graft failure potentially leading to dialysis in the case of kidney transplant recipients, the participant will be given the option to continue in the study if they remain on tacrolimus or sirolimus.","ALL","13 Years","25 Years",{"count":65,"type":66},65,"ESTIMATED","INTERVENTIONAL",[69],"NA","Can the investigators create an effective way to improve adherence to immunosuppressant medication and reduce rejection, graft loss, and death in adolescents and young adults who have undergone kidney or liver transplantation? The investigators' mobile technology intervention uses real-time electronic pillbox-assessed dose timing and text message prompts to address antirejection medication nonadherence when nonadherence is detected.",[72,73,74,75,76],"Transplant;Failure,Kidney","Transplant; Failure, Liver","Adherence, Medication","Adherence, Patient","Adherence, Treatment",[78,79,80,81,82,83,84,85],"kidney transplant","liver transplant","medication adherence","medication nonadherence","compliance","mobile health","mobile phone","technology","2026-04-09",{"date":88,"type":89},"2026-04-13","ACTUAL",{"date":91,"type":89},"2024-03-19",{"date":93,"type":66},"2026-11-30",{"name":5,"class":6},1]